江苏快乐十分网址Dr. Shisong Jiang is a clinician-turned scientist. He received his PhD degree from London School of Hygiene and Tropical Medicine in 2000. After that, he did 4.5 year¡¯s postdoctoral research at Harvard Medical School /Dana-Farber Cancer Institute in USA before working at University of Oxford working as a Principle Investigator/Clinical Research Fellow in the Department of Oncology.
One of his major contributions to science is his pioneer work to show that overlapping peptides of a viral or tumour antigen have advantages over the protein from of the same antigen and can be processed by immune system to activate both killer and helper T cells. This innovated work has applications in vaccine and diagnostic development. Since then, numerous different clinical trials around the world have been launched and the concept has been validated by promising efficacy and safety data. As a result of his work, a spinout company, Oxford Vacmedix Ltd has formed from the University of Oxford to develop cost-effective vaccines against tumours and infectious diseases.
Another novel discovery by his team is the identification of an inflammatory biomarker, inflammation enhancer (IE). IE is strongly correlated with the mortality of severe sepsis in intensive care unit (ICU) and with chronic inflammatory diseases like rheumatoid arthritis. A diagnostic and therapeutic method is being developed to identify and remove the toxic IE.
Director of Oxford Vacmedix Ltd and Oxford Vacmedix£¨Changzhou£©COMPANY., Ltd.
President of Beijing Jiahe Jinhui Venture Capital Co., Ltd.
With the company's technological inventor, Dr. Jiang Shisong, jointly promote the initial construction and development of the Company. As the president of our main investor, Beijing Jiahe Jinhui Venture Capital Co., Ltd, he has many years of company operating experience. He graduated from Tianjin University of Finance, and obtained a PhD degree in Economics and a Master of Business Administration from Nanyang Technological University in Singapore. Qualified as a certified public accountant. 2003 - 2011 he took the Vice President of Rongsheng Holding Co., Ltd., Director of Rongsheng Real Estate Development Co., Ltd. (Shenzhen Code: 002146). In 2011, he founded Beijing Jiahe Jinhui Venture Capital Co., Ltd., and is an independent director and an audit committee in Luoyang North Glass Technology Co., Ltd.
江苏快乐十分网址Director and Board of Directors of Oxford Vaccine Medical Company, UK. He is responsible for business development of the company. Dr. Coombs graduated from Oxford University. He has many years¡¯executives experience in large pharmaceutical companies such as AstraZeneca, Merck, and he was responsible for drug development and market development. He was the general manager of the Swiss biology company.
江苏快乐十分网址Graduated from Oxford University, and has been working in biotechnology companies. He has served as Director of Technical Services and Sales for British Biotech, and has served as the president of R & D Systems in Europe, one of the world's largest biological reagents companies. Currently he has been appointed as General Manager of Oxford Vacmedix ltd, and is responsible for the promotion of recombinant overlapping peptide tumor therapeutic vaccine (cervical cancer and survivin).
江苏快乐十分网址Graduated from Oxford University. He is the chairman of the British Bailey Martin Foundation, British Empire Medalist (OBE), former Chairman of the Swiss Bank Asia (Warburg). During his tenure at Warburg, he helped Bank of China to issue overseas securities and in 1995, he listed Sinopec Yizheng Chemical Fiber in Hongkong, as one of the first overseas listed companies in China. November 2009, he obtained the Outstanding Contribution Award from the Chinese Government for the contribution of the Bailey Martin Foundation to China's prevention and control of AIDS.
江苏快乐十分网址Drug Development Consultant
江苏快乐十分网址Mr. Zhu graduated from the Second Military Medical University with a bachelor's degree in medicine and a master's degree in immunology. He has more than 20 years of experience in drug development. He led the filing of the investigational new drug (IND), ¡°Rhil-1Ra eye drops¡± under category I, and completed the phase I clinical study. He was instrumental in the IND filing of category II new drugs ¡°recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) as freeze-dried powder for injection " and ¡°recombinant human granulocyte colony stimulating factor (rhG-CSF) as powder for injection¡±. He was successfully granted the new drug certificates and drug production licenses. He is very familiar with every process of a new drug development, from the production to quality control; from preclinical work to filing registration for new drug application. Moreover, he is experienced in drug production management.
He has wide pharma industry experience, having been fully responsible for both the production, and sales management of biological pharmaceuticals; improving the original product sales network and re-structuring the product sales channels.
江苏快乐十分网址She received a bachelor's and a master's degree from Northeast Normal University and a doctorate in Cologne University of Germany in 2007, Followed by postdoctoral research at Cologne University and the University of Durham, UK. In 2013, she joined Dr.Shisong Jiang¡¯s Group in Oncology Department of Oxford University. Dr. Lu is currently the R & D Director of Oxford Vacmedix£¨Changzhou£©CO., Ltd, and is responsible for the development of antibiotics, anti-tumor peptides, and diagnosis and treatment of various inflammatory diseases.
Ms. Ge graduated from Nanjing University of Science and Technology. She worked as a quality supervisor in Changzhou Pharmaceutical Factory, Hing Wo Pharmaceutical (China) and other companies. She has a wealth of experience in new factory GMP certification, review, drug production licensing, quality management System establishment and maintenance. During the period of working she undertook a national GMP review, passed two provincial GMP inspection and accepted multiple PUC GMP inspection.